Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine

American Journal of Psychiatry

Volumn 159, Issue 10, 2002, Pages 1702-1710

  Gilmor, Michelle L ^a   Owens, Michael J ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NORADRENALIN BLOOD LEVEL; NORADRENALIN UPTAKE; OUTPATIENT; PANIC; PARALLEL DESIGN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEROTONIN UPTAKE; SOCIAL PHOBIA;

ADULT; AMBULATORY CARE; CARRIER PROTEINS; DEPRESSIVE DISORDER; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SYMPORTERS; TREATMENT OUTCOME;

EID: 0036788326     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.10.1702     Document Type: Article

References (40)

1. Owens MJ, Mulchahey JJ, Stout SC, Plotsky PM: Molecular and neurobiological mechanisms in the treatment of psychiatric disorders, in Psychiatry, vol 1. Edited by Tasman A, Kay J, Lieberman JA. Philadelphia, WB Saunders, 1997, pp 210-257
2. Nelson JC: A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 1999; 46:1301-1308
3. Ressler KJ, Nemeroff CB: Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12(suppl 1):2-19
4. Steffens DC, Krishnan KRR, Helms MJ: Are SSRIs better than TCAs? comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997; 6:10-18
5. Nelson JC: Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety 1998; 7(suppl 1):5-6
6. Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234-241
7. Nelson JC, Mazure CM, Bowers Jr. MB, Jatlow PI: A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48:303-307
8. Seth R, Jennings AL, Bindman J, Phillips J, Bergmann K: Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992; 161: 562-565
9. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB: Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35:4493-4497
10. Potter WZ, Manji HK, Rudorfer MV: Tricyclics and tetracyclics, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1998, pp 199-218
11. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283:1305-1322
12. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-258
13. Beique J-C, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 1998; 349:129-132
14. Owens MJ, Knight DL, Nemeroff CB: Second generation SSRIs: human monoamine transporter binding profile of S-citalopram and R-fluoxetine. Biol Psychiatry 2001; 50:345-350
15. Owens MJ, Knight DL, Nemeroff CB: Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry 2000; 47:842-845
16. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389
17. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
18. Kenakin T: Pharmacological Analysis of Drug-Receptor Interaction. New York, Lippincott-Raven, 1997
19. Dunner DL, Dunbar GC: Optimal dose regimen for paroxetine. J Clin Psychiatry 1992; 53(suppl 2):21-26
20. Gunasekara NS, Noble S, Benfield P: Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55:85-120
21. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, Greb WH: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989; 350:60-75
22. DuBoff EA: Long-term treatment of major depressive disorder with paroxetine. J Clin Psychopharmacol 1993; 13(suppl 2): 28S-33S
23. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J: Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101: 354-359
24. Tasker TCG, Kaye CM, Zussman BD, Link CGG: Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989; 350:152-155
25. Danish University Antidepressant Group: Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18:289-299
26. Sindrup SH, Brosen K, Gram LF: Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51:288-295
27. Muscettola G, Goodwin FK, Potter WZ, Claeys MM, Markey SP: Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism. Arch Gen Psychiatry 1978; 35:621-625
28. Forsman A, Ohman R: Studies on serum protein binding of haloperidol. Curr Ther Res Clin Exp 1977; 21:245-255
29. Linkowski P, Hubain P, von Frenckell R, Mendlewicz J: Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatry Neurol Sci 1984; 234:231-236
30. Hanin I, Koslow SH, Kocsis JH, Bowden CL, Brunswick D, Frazer A, Carl J, Robins E: Cerebrospinal fluid levels of amitriptyline, nortriptyline, imipramine and desmethylimipramine. J Affect Disord 1985; 9:69-78
31. Potter WZ, Scheinin M, Golden RN, Rudorfer MV, Wowdry RW, Calil HM, Ross RJ, Linnoila M: Selective antidepressants and cerebrospinal fluid: lack of specificity on norepinephrine and serotonin metabolites. Arch Gen Psychiatry 1985; 42:1171-1177
32. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L: Fluoxetine treatment of depression. Acta Psychiatr Scand 1989; 79:586-596
33. Lundmark J, Walinder J, Alling C, Manniche PM, Dalgaard L: The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients. Eur Neuropsychopharmacol 1994; 4:1-6
34. Andrews JM, Ninan PT, Nemeroff CB: Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 1996; 4:48-56
35. Harvey AT, Rudolph RL, Preskorn SH: Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57:503-509
36. Poirier M-F, Boyer P: Venlafaxine and paroxetine in treatment-resistant depression. Br J Psychiatry 1999; 175:12-16
37. Ballus C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, Gutierrez M, Casais L, Riesgo Y: The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000; 15:43-48
38. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R: Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry 1998; 59:229-232
39. Tyrer P, Marsden CA, Casey P, Seivewright N: Clinical efficacy of paroxetine in resistant depression. J Psychopharmacol 1987; 1: 251-257
40. Javors MA, Houston JP, Tekell JL, Brannan SK, Frazer A: Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000; 3:229-235